Professional
Added to YB: 2025-10-09
Pitch date: 2025-10-01
NVO [bullish]
Novo Nordisk A/S
-19.11%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 380.00
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
turnaround
Vltava Fund New Position: Novo Nordisk A/S
NVO (new position): Bought at DKK 287-312 after historic single-day drop from DKK 1,000+ peak. Diabetes/obesity duopoly with Lilly, massive Ozempic/Wegovy demand exceeds supply. Production constraints, competition, regulatory pressure caused growth outlook cuts. High barriers, global reach 170+ countries. Long-term promising despite near-term headwinds.
Read full article (2 min)